Oncology News

Patients with cirrhosis prioritize early-detection over factors like convenience when it comes to hepatocellular carcinoma surveillance, according to study results.

In an exclusive interview with Healio Gastroenterology, Richard Finn, MD, discussed the results from a recent study of patients with hepatocellular carcinoma treated with combination therapy comprising atezolizumab, an immunotherapy drug and monoclonal antibody, and bevacizumab, another monoclonal antibody against the vascular endothelial growth factor (VEGF).

Despite having better liver function at diagnosis, Black patients with hepatitis C virus tended to have more aggressive hepatocellular carcinoma tumors compared with other racial groups, according to a study published in Cancer.

The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.

Investigators developed a validated risk score to predict post-transplant survival for patients with hepatocellular carcinoma that will help prioritize patients based on predicted survival, according to study results.

Clinicians may be able to safely perform endoscopic biliary drainage for patients with hepatocellular carcinoma with jaundice and liver dysfunction with a high technical success rate, according to a study in BMC Gastroenterology.

Healio Gastroenterology presents the following reports on the most recent research in hepatology.

Patients with alcohol-related liver disease who survive for at least 1 year after diagnosis are at increased risk for cancer, according to study results.